A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 02 May 2018
At a glance
- Drugs LY 2880070 (Primary) ; Gemcitabine
- Indications Breast cancer; Colon cancer; Colorectal cancer; Ovarian cancer; Rectal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Esperas Pharma
- 24 Apr 2018 Planned number of patients changed from 93 to 133.
- 22 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.
- 06 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Mar 2018.